David L. McKinzie

Best Publications

• Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

  Anantha Shekhar;William Z. Potter;Jeffrey Lightfoot;John Lienemann

  604
  Citations

• Diverse psychotomimetics act through a common signaling pathway.

  Per Svenningsson;Eleni T. Tzavara;Robert Carruthers;Ilan Rachleff

  367
  Citations

• 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine : a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism

  Donald R. Gehlert;Andrea Cippitelli;Annika Thorsell;Anh Dzung Lê

  349
  Citations

• Cholinergic dilation of cerebral blood vessels is abolished in M 5 muscarinic acetylcholine receptor knockout mice

  Masahisa Yamada;Kathryn G. Lamping;Alokesh Duttaroy;Weilie Zhang

  347
  Citations

• Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system

  Frank P. Bymaster;David L. McKinzie;Christian C. Felder;Jürgen Wess

  304
  Citations

• Regional heterogeneity for the intracranial self-administration of ethanol within the ventral tegmental area of female Wistar rats.

  Zachary A. Rodd-Henricks;David L. McKinzie;Robert S. Crile;James M. Murphy

  293
  Citations

• M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies.

  Eleni T. Tzavara;Frank P. Bymaster;Richard J. Davis;Mark R. Wade

  260
  Citations

• Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

  W. Y. Chan;D. L. McKinzie;S. Bose;S. N. Mitchell

  250
  Citations

• Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).

  Michael P. Johnson;David Barda;Thomas C. Britton;Renee Emkey

  246
  Citations

• Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity.

  Frank P. Bymaster;Petra A. Carter;Masahisa Yamada;Jesus Gomeza

  228
  Citations

• Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice.

  E T Tzavara;F P Bymaster;C C Felder;M Wade

  213
  Citations

• Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

  Bruce J. Kinon;Bruce J. Kinon;Brian A. Millen;Lu Zhang;David L. McKinzie

  209
  Citations

• Cocaine Is Self-Administered into the Shell but Not the Core of the Nucleus Accumbens of Wistar Rats

  Zachary A. Rodd-Henricks;David L. McKinzie;Ting Kai Li;James M. Murphy

  202
  Citations

• Muscarinic mechanisms of antipsychotic atypicality.

  Frank P. Bymaster;Christian C. Felder;Eleni Tzavara;George G. Nomikos

  199
  Citations

• LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.

  Linda M. Rorick-Kehn;Jeffrey M. Witkin;Michael A. Statnick;Elizabeth L. Eberle

  188
  Citations

• In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

  Linda M. Rorick-Kehn;Bryan G. Johnson;Karen M. Knitowski;Craig R. Salhoff

  187
  Citations

• Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.

  Katie Leach;Richard E Loiacono;Christian C Felder;David L McKinzie

  178
  Citations

• Role for M5 muscarinic acetylcholine receptors in cocaine addiction.

  Anders Fink-Jensen;Irina Fedorova;Gitta Wörtwein;David P. D. Woldbye

  164
  Citations

• Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039)

  Linda M. Rorick-Kehn;Bryan G. Johnson;Jennifer L. Burkey;Rebecca A. Wright

  155
  Citations

• Elucidating the role of muscarinic receptors in psychosis.

  Christian C. Felder;Amy C. Porter;Tiffanie L. Skillman;Lu Zhang

  154
  Citations